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Abstract
Lymphoblastoid cell lines (LCLs) are commonly used in molecular genetics, supplying DNA for the HapMap and 1000
Genomes Projects, used to test chemotherapeutic agents, and informing the basis of a number of population genetics
studies of gene expression. The process of transforming human B cells into LCLs requires the presence of Epstein-Barr virus
(EBV), a double-stranded DNA virus which through B-cell immortalisation maintains an episomal virus genome in every cell
of an LCL at variable copy numbers. Previous studies have reported that EBV alters host-gene expression and EBV copy
number may be under host genetic control. We performed a genome-wide association study of EBV genome copy number
in LCLs and found the phenotype to be highly heritable, although no individual SNPs achieved a significant association with
EBV copy number. The expression of two host genes (CXCL16 and AGL) was positively correlated and expression of ADARB2
was negatively correlated with EBV copy number in a genotype-independent manner. This study shows an association
between EBV copy number and the gene expression profile of LCLs, and suggests that EBV copy number should be
considered as a covariate in future studies of host gene expression in LCLs.
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Introduction
Epstein-Barr virus (EBV) is a ubiquitous human gammaherpes-
virus. Following primary infection EBV establishes lifelong
persistent infection through latent infection of memory B cells
where the virus genome is transcriptionally silent [1,2]. Reactiva-
tion from latency is required for the production of infectious EBV,
with such lytic EBV replication being under the control of host
and virus factors. In particular, terminal differentiation of memory
B cells into plasma cells can lead to EBV lytic reactivation [3]. The
mechanisms of host induction of EBV lytic replication are
incompletely understood, but periodic shedding of EBV in saliva
[4] and variation in saliva virus load between people [5] suggest
host genetic variation may contribute to EBV lytic cycle induction.
Lymphoblastoid cell lines (LCLs) are human B cells immortalised
in vitro by EBV and are a useful model of latent infection of B
cells. Previous studies on LCLs have shown that when multiple
LCLs are derived from the same individual, inter-individual
variation in EBV copy number in LCLs is greater than intra-
individual variation [6]. A study of the impact of EBV copy
number on the gene expression profiles of 198 HapMap LCLs
reported that expression of 125 human genes was significantly
correlated with EBV copy number [7]. A comparison of Epstein-
Barr virus copy number in 62 adult and paediatric LCLs found
considerable inter-individual variation in EBV copy number that
correlated with expression of immediate-early viral lytic genes
BRLF1 and BZLF1, suggesting that spontaneous lytic reactivation
is the cause of high EBV genome copy numbers in a subset of
LCLs. After the addition of acyclovir, a drug which inhibits viral
reactivation, Davies et al. showed EBV genome copy numbers fall
in LCLs, and return to previous high levels after the removal of
acyclovir [8]. This suggests that spontaneous lytic reactivation may
be under the control of cell-intrinsic factors. When the viral gene
expression profiles of LCLs were compared, using RNAseq data
from multiple experiments from different laboratories, Arvey et al.
[9] reported two major EBV gene expression profiles: latency type
III and a lytic pattern of expression. There is evidence of both
BZLF1 expression and virus particle production in some LCLs
[10]. We have therefore hypothesised that high EBV copy number
in LCLs is the result of poor host cell control of the EBV latent-
lytic cycle switch, and may be under the control of host genetic
factors.
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Genome-wide association studies have been successfully used to
identify the host genes involved in the pathogenesis of infectious
disease [11,12,13,14,15]. Two genome-wide association studies of
genetic control of antibodies to herpesviruses have been
performed. A study of EBV antibody titres in ,2000 individuals
identified 15 loci exceeding genome-wide significance associated
with either the quantitative or discrete trait of antibody titre [16].
By contrast, a similarly-sized study of cytomegalovirus (CMV)
antibody response, a betaherpesvirus which also establishes
lifelong latent infection in humans, did not find any genome-wide
significant associations [17]. Other studies of host genetic response
to herpesvirus infection and lytic reactivation have been limited to
family linkage [18] and candidate gene [19] studies of herpes
simplex virus-induced disease, and small studies of susceptibility to
infection of chickens with an avian herpesvirus, Marek’s disease
virus [20,21]. As yet, there have been no attempts to characterise
common human genetic polymorphisms associated with cell-
intrinsic response to EBV infection.
Here we describe a study to identify human genetic variants
associated with Epstein-Barr virus genome copy number in the
HapMap [22] and 1000 Genomes [23] LCLs, incorporating
sequencing and genotyping data from the HapMap and 1000
Genomes projects. We also investigate differences in gene
expression associated with EBV genome copy number using
publicly available gene expression data for a subset of the HapMap
3 samples [24].
Results
Relative EBV copy number in LCLs and
between-population comparisons
We determined the relative EBV genome copy number for 915
LCLs from the HapMap and 1000 Genomes populations using
quantitative PCR (qPCR). The qPCR assay had an 8 log10
dynamic range from 16109 to 16102 copies/reaction (Figure S1)
and an analytical sensitivity of 100 copies/reaction. The PCR
efficiency was 99.4%. The samples assayed included individuals
from 12 populations (Table 1); and EBV copy numbers of all
samples were within the dynamic ranged of the qPCR. Across all
populations the mean relative (to single copy host gene) EBV copy
number per LCL is 23.36 with a range of 16.07–29.02 (SD62.03),
corresponding to an absolute range of 1 copy per cell to 350 copies
per cell (Figure 1 A). We examined the trait of EBV copy number
in different populations (Figure 1 B), and found significant
differences in the mean EBV copy number between the
populations (ANOVA p,2.2610216). Interestingly, apparently
similar ethnic groups in different geographical areas have different
mean EBV genome copy numbers. The Denver Han Chinese
(CHD) and Beijing Han Chinese (CHB) populations have
statistically significantly different means (difference =23.23, 95%
CI 24.34–22.12), p = 1.1761028), although the CHB and
Japanese from Tokyo (JPT) do not differ from one another
significantly. Some European ancestry populations also differ from
one another in their mean EBV copy number: Toscani from Italy
(TSI) differ from CEU (European ancestry in Utah, USA)
(difference =21.63, 95% CI 22.52–20.74, p= 261027).
Association testing
Using the entire sample set we performed a genome wide
association study for common host genetic variants associated with
LCL EBV copy number. To determine if the EBV that
immortalised the LCLs was the laboratory strain B95.8 rather
than outgrowth of spontaneous LCLs with wild type EBV we
assembled the EBV genomes from 77 CEU and YRI LCLs. We
looked for the presence of the deletion specific for the B95.8
genome, which was present in every LCL studied. The frequency
of spontaneous LCLs containing wild type EBV, and/or LCLs
immortalised with B95.8 and co-infected with wild type EBV, is
therefore less than 1 in 77.
After sample-level quality control, genome-wide sequence and
genotype data were available for 899 samples from the 1000
Genomes Phase I and HapMap Phase III consensus releases.
Mixed-effects modelling [25] was used to test each variant
individually for association with EBV copy number in LCLs.
Samples without full human genome sequence data were imputed
using 1000 Genomes information [26]. Variants were taken
forward to association analysis if they were observed to vary in all
12 populations studied with a frequency of .1% and a minimum
imputation quality of 0.9. This created a set of 1.66106 SNPs in
common between the samples. The sample size of phenotyped
LCLs with genotype or whole genome sequence information
available is 899 individuals, including 798 unrelated individuals,
once offspring of 101 trios were removed. The statistical power of
Table 1. Samples used in this study.
Population code Population description* N (samples) N (trios) N (duos)
ASW People with African Ancestry in the Southwest United States 89 13 21
CEU Utah residents with ancestry from Northern and Western Europe 84 27
CHB Han Chinese in Beijing, China 44
CHD Han Chinese in Denver, Colorado 55
GIH Gujarati Indians in Houston, Texas 90 1
IBS Iberian Populations in Spain 99 1
JPT Japanese in Tokyo, Japan 44
LWK Luhya in Webuye, Kenya 5
MKK Maasai in Kinyawa, Kenya 140 21 5
MXL People with Mexican Ancestry in Los Angeles, California 92 24
TSI Toscani in Italia 67
YRI Yoruba in Ibadan, Nigeria 90 30
*Population names from 1000 Genomes [48] and HapMap [22].
doi:10.1371/journal.pone.0108384.t001
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the study to detect a variant explaining a given proportion of the
total trait variance was calculated using GWApower [27]. Our
study had an 80% power to detect a variant explaining 4.7% of the
total variance in relative EBV copy number. The overall
distribution of P values showed little evidence of genomic inflation
(l=0.98), consistent with the null hypothesis and suggesting that
mixed-effects modelling was able to correct for high familial
relatedness and population structure (Figure 2 A and B).
We estimated the proportion of variance in EBV copy number
within the dataset explained by the set of ,1.6 million common
genetic variants using GCTA, in 677 unrelated individuals to be
0.65 (SE 60.38; p = 0.04). We also calculated the heritability of
EBV copy number in 101 trios present within the 1000 Genomes
dataset, where EBV copy number was available for all trio
members. The parental mid-point EBV copy number was
regressed against the offspring EBV copy number, giving a
heritability estimate of 34% (SE 611, p = 0.0028).
No variants passed the genome-wide significance threshold (P,
561028, Figure 2 A), although 98 SNPs achieved a genome wide
significance of ,161025 and are suggestive of a possible
association (Table S2 in File S1). Of these the top SNP,
rs10959089 (P= 1.1761026, beta = 0.52 for the minor C allele),
was located in the first intron of the gene PTPRD (protein tyrosine
phosphatase receptor delta) (Figure 2 C).
Association testing of variants implicated in EBV
infection, immune response and disease by previous
studies
48 SNPs and small structural variants have been previously
reported to influence EBV traits such as acquisition risk, antibody
response, or EBV-positive disease risk. 28 of these SNPs were
included in our association study (Table 2). Two SNPs had P
values of nominal significance (rs2516049, p = 0.01; rs1052536,
p = 0.03). It is therefore not possible to link these variants to the
phenotype of relative EBV copy number in LCLs.
Epstein-Barr virus gene copy number, host gene
expression and eQTL analysis in LCLs
Microarray gene expression data was available for 466
unrelated individuals from 8 populations [24]. A linear regression
was performed for these individuals between 21,800 gene
transcripts and EBV genome copy number. A statistically
significant positive correlation was found between EBV relative
copy number and the expression levels of two genes: CXCL16
(chemokine (C-X-C motif) ligand 16) and AGL (amylo-alpha-1, 6-
glucosidase, 4-alpha-glucanotransferase), and a statistically signif-
icant negative correlation between EBV relative copy number and
ADARB2 (adenosine deaminase, RNA-specific, B2) expression
(Figure 3; Table 3). Transcripts with suggestive P values (P.
561023) are included in Table S3 in File S1. Evidence for the
effect of EBV genome copy number on eQTL results was not
observed for any of these genes; the correlation did not occur in a
genotype-dependent manner. QTL mapping using EBV as a
phenotype did not reveal any statistically significant SNPs located
in or near these genes.
Discussion
This is the largest study to investigate the impact of host genetic
factors on Epstein-Barr virus genome copy number in lympho-
blastoid cell lines. As inhibitors of the EBV lytic cycle effectively
reduce EBV copy number in LCLs this suggests the higher copy
numbers are the result of lytic replication induction [8]. Our study
therefore also represents a proxy phenotype for the spontaneous
switch from latent to lytic EBV replication in LCLs. We identified
the EBV strain infecting a sample of the LCLs, quantified relative
EBV genome copy number in 915 LCLs from the HapMap and
1000 Genomes study, performed a genome-wide association study
of EBV genome copy number, estimated the heritability of EBV
genome copy number in parent-offspring trios, and examined the
relationship between EBV genome copy number and human gene
expression in a subset of LCLs.
Figure 1. Distribution of relative EBV copy number in LCLs
from 12 populations. A. Relative EBV copy number in 915 LCLs from
12 populations, including 97 parent-offspring trios. Range 16.07–29.02,
mean 23.36 (SD62.03). The data are not normally distributed (Shapiro-
Wilk: W= 0.977, p-value = 2.086211). B. Box and whisker plots showing
the range (dotted lines), interquartile range (coloured boxes) and mean
relative EBV copy number (central vertical lines) for the 12 populations
included in this analysis.
doi:10.1371/journal.pone.0108384.g001
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Using high-coverage sequence data from the 1000 Genomes
Pilot project for 77 CEU and YRI LCLs, we estimate that the rate
of LCLs containing wild-type or non-B-95.8-strain EBV is less
than 1 in 77. This is consistent with the findings of Santpere and
colleagues [25], who detected unambiguous evidence of EBV co-
infection or wild-type infection in 10 out of 929 LCLs from the
1000 Genomes Project dataset. These 10 LCLs were not included
in our analysis, therefore competition between viral strains was
unlikely to be a factor influencing copy number in our study.
Our results, of relative EBV copy number varying between
individuals, and within and between populations are consistent
with previous studies [6,8] of LCLs of unreported ancestry, where
EBV genome copy number was a trait that varied more
significantly between LCLs than between different passages or
sub-cultures of the same LCL. Davies et al. [8] suggest that the
variation in EBV copy number is controlled by cell-intrinsic
factors. In our analysis, it remained unclear whether genetic or
cell-intrinsic factors caused the differences in mean EBV copy
number between the Denver Han Chinese (CHD) and Beijing
Han Chinese (CHB) populations. While it has been noted that the
CHD LCLs grow more slowly than the Asian (ASN) LCLs (which
include the CHB LCLs) [28], another study [29] found no
statistically significant relationship between LCL growth rate and
EBV copy number. We conclude that although cell intrinsic
factors are still the most plausible explanation, multiple genetic
variants, each with a small effect of EBV copy number, also likely
play a role.
The strongest association signal in the genome-wide association
study was an intronic SNP, located in gene PTPRD. PTPRD
functions in cellular signalling, is located on the cell surface, and
has been identified as a tumour suppressor. Mutations within
PTPRD have been associated with several cancers: glioblastoma
multiforme and head and neck squamous cell carcinomas [30],
and clear cell renal carcinoma [31]. The paralogous gene PTPRK
(protein tyrosine phosphatase receptor kappa) interacts with EBV.
When PTPRK is over-expressed in EBV-infected Hodgkin
lymphoma cells, survival of these cells decreases; when PTPRK
expression is knocked down by RNAi, survival increases;
suggesting a role for PTPRK in tumour suppression. The EBV
gene EBNA1 targets Smad2, a protein that regulates PTPRK
expression. By decreasing the half-life of Smad2, PTPRK is down-
regulated in turn [32]. PTPRC (protein tyrosine phosphatase
receptor C) has recently been associated with herpes simplex
encephalitis susceptibility in mice [33]. Therefore although not
genome wide significant, polymorphisms in PTPRD are in a
biologically plausible gene.
Changes in the relative EBV copy number of LCLs have an
impact on the gene expression profiles of those LCLs in a
genotype-independent manner. Our analysis of genes differentially
expressed between LCLs identified three genes whose expression
positively (CXCL16 and AGL) or negatively (ADARB2) correlated
with relative EBV copy number. CXCL16 is regulated by the
microRNA CMVmiR-M23-2 of another human herpesvirus,
CMV [34]. Reptar [35] predicts that CXCL16 is targeted by
seven EBV microRNAs (ebv-miR-BART17-5p, ebv-miR-
BART21-3p, ebv-miR-BART21-5p, ebv-miR-BART22, ebv-
miR-BART3*, ebv-miR-BART5* and ebv-miR-BART7). It is
also interesting to note that CXCL16 is a chemokine which has
recently been associated with disease activity in multiple sclerosis
[36] and mouse models of experimental autoimmune encephalo-
myelitis [37]. EBV microRNAs are also predicted to interact with
AGL and ADARB2 [35]. It is likely that in a larger sample of
LCLs, further genes would show significant correlations with
relative EBV copy number. It is therefore important to control for
the effects of EBV copy number in gene expression studies utilising
large samples of LCLs. Other studies of the impact of EBV on the
gene expression patterns of LCLs include a study by Choy et al.,
which reported that ,15% of genes to have at least 5% of their
variance correlated with EBV copy number [7].
In a study of semi-quantitative antibody response to EBV gene
EBNA1, Rubicz et al. [38] were able to identify 15 SNPs which
were associated with EBV antibody response at genome-wide
significant level. In contrast, Kuparinen et al. [17] performed a
GWAS for CMV antibody response and did not identify any
genome-wide significant SNPs. It is possible that a different genetic
architecture underlies the host response to control of EBV copy
number in LCLs than that of EBV antibody response. Additionally
Figure 2. Manhattan plots of the association between EBV copy
number and human genetic variants in LCLs. A. Results of the
stage 2 GWAS of relative EBV copy number in 899 LCLs, derived from 12
populations. In total, ,1.6 M SNPs, polymorphic in every population
studied, were analysed using FaST-LMM. Each point represents a SNP.
There were no SNPs with genome-wide significant p-values after
correction for multiple testing. B. QQ plot showing the distribution of
observed test statistics plotted against the expected (null) distribution
(red line). The SNPs which fall below the red line suggest that the GWAS
may be losing power to detect SNPs associated with EBV copy number.
C. The strongest signal is located within an intron of protein tyrosine
phosphatase receptor delta (PTPRD), SNP rs10959089 (p = 1.17610-6).
Plot C made with LocusZoom [56].
doi:10.1371/journal.pone.0108384.g002
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all of the genes associated with the EBV antibody response were
within the HLA system, a region of the genome this study was not
well-powered to interrogate given the differences in HLA allele
frequencies between populations and our criteria that a variant
must be present in all 12 populations studied for SNP inclusion.
Our finding that the 1.6 M SNPs studied in this GWAS could
collectively explain 65% (se = 38%) of the variance in relative EBV
copy number, while no single SNP reached genome-wide
significance, suggests that many variants of small effect play a
collective role within LCLs. Similarly, GWAS of genetic resistance
to HIV-1 infection [15] could not find any common variants (with
the exception of CCR5-delta 32) which were protective, while
GWAS of host control of HIV-1 viral load found a number of
genome-wide significant loci associated with lower HIV-1 viral
load set points and slower progression to AIDS [12,39]. The
power to identify host genetic variation of virus infection traits may
greatly depend on the trait under study and the sample sizes.
We estimated the heritability of relative EBV copy number,
based on data from 101 parent-child trios to be 34% (se 611%,
p= 0.003). Other studies have found EBV anti-EBNA1 antibody
response to be 68% heritable when considered as a discrete trait
(seropositive versus seronegative) [38] and discrete anti-VCA IgG
antibody response to be 32–48% heritable [40]. Infectious
mononucleosis concordance rates in twins were estimated to be
12% between monozygotic twins and 6% between dizygotic twins
[41]. Therefore, host genetic factors appear to play a variable but
significant role in symptomatic response to primary EBV infection,
the adaptive immune response to EBV latency, and the cell-
intrinsic control of EBV latency although none of the variants
previously identified were significantly associated with EBV copy
number in our analysis.
This study has established that relative EBV copy number
within LCLs is very much a complex trait, which has a significant
heritable component. Our results suggest that many genetic
variants of effect size less than 4.7% of variance in relative EBV
copy number exist, but which this study was not statistically
powered to detect. This study also focused on 1.6 million single
nucleotide polymorphisms which were common to every popula-
tion studied. Because SNPs which did not vary in all 12
populations studied were excluded from this analysis due to
potential population stratification, we cannot rule out the effect on
relative EBV copy number of SNPs which were only variable in a
subset of the populations studied. We also cannot exclude the
effects of rare variants of large effect on relative EBV copy number
in LCLs, as these were not studied here. It is also possible that
structural variants which are poorly tagged by common SNPs may
play a role. To identify the genetic factors that underpin EBV copy
number, a significant increase in sample size is necessary that will
become possible within on-going large-scale sequencing and
genotyping projects. However, we do find that even in a relatively
modest sample size, EBV copy number is correlated with LCL
host-gene expression patterns, in a host genotype-independent
manner. Studies using larger samples of LCLs to study host gene
expression profiles may find EBV-associated changes in LCLs
Figure 3. Association between EBV copy number and human gene expression in LCLs. Manhattan plot showing the correlation between
expression levels of 21,800 individual gene transcripts from microarray data and EBV copy number.
doi:10.1371/journal.pone.0108384.g003
Table 3. Gene transcripts associated with relative EBV copy number with P,361025.
Gene Array_tag Chr Beta SE P value
CXCL16 ILMN_1672278 17 0.114 0.019 2.461029
AGL ILMN_1680343 1 0.039 0.007 9.361028
ADARB2 ILMN_1749493 10 20.042 0.009 2.361026
doi:10.1371/journal.pone.0108384.t003
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generate false-positive results, unless EBV copy number is
controlled for.
Methods
Ethics
No primary human tissue was used in this study. Details of this
project were sent to the Coriell Cell Repository to be passed on the
relevant Community Advisory Groups for HapMap participants.
Samples
Separated from peripheral blood as part of the HapMap and
1000 Genomes Projects, LCLs and LCL-derived DNA were
provided to Wellcome Trust Sanger Institute by the Coriell Cell
Repository. DNA from 915 HapMap lymphoblastoid cell lines was
obtained from Coriell Institute for Medical Research, representing
12 populations. A summary of the composition of the sample
group that provided the LCLs is provided in Table 1. Cell line
BCBL-1 was used as a calibrator for quantitative PCR. It is a
Kaposi Sarcoma Herpesvirus-positive, EBV-negative body cavity-
derived primary effusion lymphoma cell line, of B cell origin [42].
Quantification of relative EBV copy number per cell
Quantification of relative EBV copy number was performed
using quantitative PCR (qPCR). An artificial gene (GeneArt, Life
Technologies) was designed based on the EBV BALF5 sequence
for use as a positive control in qPCR, but containing an artificially
inserted sequence to distinguish it from wild-type BALF5, with the
sequence: CCCTGTTTATCCGATGGAATGACGGCGCATTTC-
TCGTGCGTGTACACCGTCTCGAGTATGACTGGTTCCAATT-
GACAAGCTGGGTCGTAGACATGGAAGTCCAGAGGGCTTC-
CG. Quantitative PCR was performed on an Agilent MxPro 3005
machine using the QuantiTect Multiplex PCR NoROX Kit
(Qiagen). The PCR reagents were: 2.5 ml nuclease-free water
(Qiagen), 12.5 ml QuantiTect Multiplex PCR No ROXmastermix
(Qiagen), 2 ml BALF5 primer mix (10 pmol/ml of each primer and
0.75 pmol/ml probe [43]), 2 ml GAPDH primer mix (2.5 pmol/ml
of each primer and 2 pmol/ml probe [44]), 1 ml ROX (diluted 1:10
in 10 mM Tris-HCL (Life Technologies)), and 5 ml template DNA
or positive control. EBV qPCR primer and probe sequences were
from Kimura, 1999 [43]. GAPDH primer and probe sequences
were from Pardieu, 2010 [44]. PCR conditions were as follows:
95uC for 15 minutes, followed by 45 cycles of 94uC for 60 seconds,
57uC for 30 seconds and 72uC for 30 seconds. Fluorescence data
was collected during the annealing step.
The 22DDCT method [45] was used for relative quantification
of target gene abundance (target gene BALF5, endogenous control
gene GAPDH). Gene copy numbers in LCLs were normalised
against the BCBL-1 cell line [46]. Data analysis was performed
using MXPro v4.10 qPCR software (Agilent Technologies).
Heritability analysis
Within the individuals with relative EBV copy number data
available, there were 101 trios with EBV copy number informa-
tion available for mother, father and offspring. The family
structure was taken from the 1000 Genomes pedigree files. They
were drawn from four populations - CEU, IBS, MXL and YRI.
The mid-parental average for the phenotype (relative EBV copy
number) was calculated and the child’s phenotype regressed
against the mid-parental phenotype. The regression gives an
estimate of narrow sense heritability of the trait and its associated P
value.
Genotyping
899 samples have been sequenced or genotyped using three
different platforms. For 355 samples, sequencing data was
available from the 1000 Genomes Project Phase 1 release
(http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results
/integrated_call_sets/); for 313 samples, genotypes was available
from the 1000 Genomes Project Illumina HumanOmni2.5–Quad
v1-0 B_SNP data release (ftp://ftp.1000genomes.ebi.ac.uk/vol1/
ftp/technical/working/20120131_omni_genotypes_and_intensities/
); and for 231 samples, genotypes were available from the HapMap
Phase III consensus release (ftp://ftp.ncbi.nlm.nih.gov/hapmap/
genotypes/2009-01_phaseIII/plink_format/). Where multiple sourc-
es of genotyping or sequencing data were available for a sample, 1000
Genomes Phase I sequence data was used in preference to other
sources, followed by Illumina 2.5 M Omni genotypes, and finally
HapMap Phase III genotypes. Briefly, quality control for SNP and
sample inclusion was as follows: Hardy-Weinberg equilibrium P
value of .161026; minor allele frequency of .1%; SNP call rate of
.95%; and a sample call rate of .95%. Monomorphic SNPs were
excluded. All quality control was performed using PLINK [47].
Imputation and association testing
The statistical power to identify a genetic variant was calculated
using GWApower [27]. Imputation of genotyped samples to 1000
Genomes Phase 1 was performed using IMPUTE2 [26]. This
increased the number of SNPs in common between the samples
from 600,000 to 37 million. These imputed variants were then
subjected to quality control in PLINK [47], namely removing:
SNPs where Hardy-Weinburg equilibrium was P,161025 in at
least one of the 1000 Genomes populations (n = 8,754,733); SNPs
which were monomorphic among phenotyped samples
(n = 8,689,910); SNP with a missingness .0.01 (n = 9,808,778)
and all SNPs with MAF,0.01 (n= 16,881,983). SNPs which were
called discordantly in samples where sequencing and genotyping
information were both available were excluded from further
analysis. As EBV copy number varies significantly between
different populations, we performed additional QC in order to
account for potential stratification in the association analysis:
removing any SNP if HWE P,0.01 in two or more populations,
and removing any SNP that was monomorphic in at least one of
the populations. This left a final set of 1,595,489 SNPs which were
polymorphic in every population studied. Association analysis was
performed using a linear mixed model implemented in FaST-
LMM-Select [25].
Transcriptional profiles
Microarray expression data from Stranger et al. [24] (‘‘RE-
DUCED’’ dataset) was obtained for 466 unrelated individuals with
relative EBV copy numbers. Expression data is available on
http://www.ebi.ac.uk/arrayexpress/(Series Accession Number E-
MTAB-264 and E-MTAB-198.processed.1). For each individual,
correlation between expression levels of individual gene transcripts
and EBV copy number was determined via linear regression. P-
values of correlation with EBV copy number were obtained for
each gene transcript (21,800 in total). Transcripts with p-value
lower than 561026 were considered significantly correlated with
EBV copy number. Transcripts were mapped back to the genes
they correspond to according to the array design file (‘‘A-MEXP-
930.adf.txt’’) available on http://www.ebi.ac.uk/arrayexpress/
experiments/E-MTAB-264/
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eQTL analysis
Effect of EBV relative copy number on the identification of
expression quantitative loci (eQTLs) was tested in PLINK via
linear association model with or without EBV copy number used
as a covariate. Expression data included normalized log2
quantitative gene expression measurements for the 21,800 probes
(18,226 unique autosomal genes) from 466 unrelated individuals of
HapMap Phase III assayed on the Illumina Sentrix Human-6
Expression BeadChip [24]. SNP genotypes were as described for
the QTL analysis. SNPs within a 2 Mb window around a gene
locus were defined as eQTLs. Correction for population structure
was performed using principal component analysis (PCA).
Difference in effect sizes of eQTLs identified in the two association
studies (with or without EBV copy number as a covariate) was
determined via paired t-test across all tested SNPs (1.6 million).
Resulting p-values of the difference in effect sizes were plotted for
each transcript across all 22 non-sex chromosomes.
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polymerase gene BALF5. The efficiency of the BALF5 qPCR
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